Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma

Radiation Oncology

Michael G Haddock¹  Robert C Miller¹  Kenneth R Olivier¹  Brandon M Barney² 

[1] Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA;Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

关键词: Locally advanced;    Cholangiocarcinoma;    Stereotactic radiosurgery;    Stereotactic body radiotherapy;   

Others  :  1160849
DOI  :  10.1186/1748-717X-7-67

 received in 2012-03-29, accepted in 2012-04-26,  发布年份 2012

【 摘 要 】

Background

To report single-institutional clinical outcomes and toxicity with SBRT for cholangiocarcinoma.

Methods

From March 2009 to July 2011, 10 patients with 12 unresectable primary (n = 6) or recurrent (n = 6) cholangiocarcinoma lesions underwent abdominal SBRT. Sites treated included liver (n = 10), abdominal lymph nodes (n = 1), and adrenal gland (n = 1). SBRT was delivered in three (n = 2) or five (n = 10) consecutive daily fractions over one week. The median prescription dose was 55 Gy (range, 45–60). Treatment response was graded by RECIST v.1.1, and toxicities were scored by CTCAE v.4.0. Data was analyzed using the Kaplan-Meier method to determine rates of local control (LC), freedom from distant progression (FFDM) and overall survival (OS).

Results

The median follow-up was 14 months (range, 2–26 months). LC, defined as freedom from progression within the SBRT field, was 100%, but four patients treated to intrahepatic sites experienced progression elsewhere in the liver. Estimates for FFDM at 6 and 12 months were 73% and 31%, respectively. Sites of disease relapse included liver (n = 3), liver and lymph nodes (n = 1), liver and lungs (n = 1), lymph nodes (n = 1), and mesentery (n = 1). OS estimates for the cohort at 6 and 12 months were 83% and 73%, respectively. The most common Grade ≥2 early toxicities were Grade 2 nausea and vomiting (n = 5) and gastrointestinal pain (n = 2). Late ≥2 toxicities included Grade 2 gastrointestinal pain (n = 3), Grade 3 biliary stenosis (n = 1), and Grade 5 liver failure (n = 1).

Conclusions

SBRT shows promise as an effective local therapy for properly-selected patients with cholangiocarcinoma. Further follow-up is needed to better quantify the risk of late complications associated with SBRT.

【 授权许可】

   
2012 Barney et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jarnagin WR, Fong Y, DeMatteo RP, et al.: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001, 234:507-517. discussion 517–509
• [2]Rea DJ, Heimbach JK, Rosen CB, et al.: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242:451-458. discussion 458–461
• [3]Jarnagin WR, Ruo L, Little SA, et al.: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003, 98:1689-1700.
• [4]Ben-Josef E, Normolle D, Ensminger WD, et al.: Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005, 23:8739-8747.
• [5]Crane CH, Macdonald KO, Vauthey JN, et al.: Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002, 53:969-974.
• [6]Kim JH, Won HJ, Shin YM, et al.: Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011, 196:W205-W209.
• [7]Kim JH, Yoon HK, Sung KB, et al.: Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008, 113:1614-1622.
• [8]Tomizawa Y, Tian J: Photodynamic therapy for unresectable cholangiocarcinoma. Dig Dis Sci 2012, 57:274-283.
• [9]Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24:115-125.
• [10]Alden ME, Mohiuddin M: The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994, 28:945-951.
• [11]Deodato F, Clemente G, Mattiucci GC, et al.: Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2006, 64:483-488.
• [12]Goodman KA, Wiegner EA, Maturen KE, et al.: Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:486-493.
• [13]Herfarth KK, Debus J, Lohr F, et al.: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
• [14]Kopek N, Holt MI, Hansen AT, et al.: Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010, 94:47-52.
• [15]Polistina FA, Guglielmi R, Baiocchi C, et al.: Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol 2011, 99:120-123.
• [16]Tse RV, Hawkins M, Lockwood G, et al.: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664.
• [17]Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
• [18]Ortner ME, Caca K, Berr F, et al.: Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003, 125:1355-1363.
• [19]Barney BM, Olivier KR, Macdonald OK, et al.: Clinical Outcomes and Dosimetric Considerations Using Stereotactic Body Radiotherapy for Abdominopelvic Tumors. American journal of clinical oncology 2011.
• [20]Benedict SH, Yenice KM, Followill D, et al.: Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010, 37:4078-4101.
• [21]Pan CC, Kavanagh BD, Dawson LA, et al.: Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76:S94-S100.
• [22]Levitsky J, Sorrell MF: Hepatic complications of hematopoietic cell transplantation. Curr Gastroenterol Rep 2007, 9:60-65.